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Introduction
Plasmacytoid dendritic cells (pDCs) are “professional” type I 
IFN-producer cells that play a central role in host antiviral immu-
nity (1, 2). Typically present at low frequency in peripheral blood, 
they migrate to sites of infection and, when activated, produce 
prodigious quantities of IFN-α. Activated pDCs also secrete proin-
flammatory cytokines, upregulate surface expression of matu-
ration markers, present antigens, and thereby contribute signifi-
cantly to CD4+ T cell and B cell development (3, 4). Thus, these 
cells effectively bridge innate and adaptive antiviral immunity. 
pDCs primarily sense viruses via endosomal TLR7 and TLR9 (5), 
but they can also sense viral nucleic acids in the cytosol (6).
Although early studies suggested that peripheral blood mono-
nuclear cells are stimulated to produce IFN-α more efficiently 
by enveloped viruses compared with nonenveloped viruses (7), 
more recent studies indicate that pDCs are activated by exposure 
to both types of viruses (4, 8). Nonetheless, some picornaviruses 
(aphthoviruses and some strains of coxsackievirus B) activate 
pDCs only in the presence of antiviral antibodies, suggesting that 
uptake of the virus is limiting and requires Fc receptors (9, 10). 
Internalization thus appears to be critical for sensing of picornavi-
ruses by pDCs, while replication of the viral genome is not always 
required. Hepatitis A virus (HAV) is an unusual member of the 
Picornaviridae that has two mature infectious forms, one that is 
wrapped in host cell membranes (enveloped) and one that is not 
(11). The enveloped form of the virus (eHAV) is the predominant if 
not the only form of the virus released into the peripheral circula-
tion during acute hepatitis A, and it is distinct from the more typ-
ical nonenveloped “naked” picornaviral virions shed in feces (11). 
The near absence of type I IFN-stimulated gene (ISG) expression 
is a striking feature of acute HAV infection in primates (12), calling 
into question whether pDCs are capable of sensing the very large 
amounts of eHAV produced within the liver.
HAV is highly hepatotropic, and infection with HAV typi-
cally causes moderate to severe acute inflammatory liver injury. 
Although it appears incapable of establishing persistent infec-
tions even in immunocompromised persons (13), HAV shares 
common strategies for evasion of innate immune responses with 
hepatitis C virus (HCV), also a positive-strand RNA virus, but one 
that is uniquely capable of establishing long-term persistence in 
most infected adults. Both HAV and HCV express proteases that 
degrade mitochondrial antiviral signaling protein (MAVS) and 
TIR- domain-containing adapter-inducing IFN-β (TRIF, also known 
as TICAM1), key adaptor molecules for retinoic acid–inducible gene 
I–like (RIG-I–like) receptor (RLR) and TLR3-mediated induction of 
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stimulate pDCs either in the presence or absence of anticapsid 
antibody (Figure 1A). The lack of IFN-α production was not due 
to active suppression of pDCs, since HAV had no effect on IFN-α 
production induced by CpG-A, R848 (a TLR7 agonist), or influ-
enza A virus (Figure 1B). However, pDCs secreted abundant 
IFN-α when cocultured with Huh-7.5 hepatoma cells infected 
with low passage, noncytopathic HAV (ref. 23 and Figure 1A). 
These results were reproduced with pDCs from multiple donors 
(Figure 1C). pDCs were also activated when cocultured with 
infected fetal Rhesus monkey kidney (FRhK-4) cells (Figure 
1C). Neither antibody to the putative HAV cellular receptor, 
T cell immunoglobulin mucin family member 1 (TIM1, also 
known as HAVCR1) (24), nor neutralizing anti-HAV antibody 
blocked this response (Figure 1D), suggesting that it is not 
induced by nonenveloped HAV virions.
IFN-α production was ablated by coculturing pDCs with 
infected Huh-7.5 cells in the presence of chloroquine or bafi-
lomycin A1 (Figure 1D, middle), suggesting a requirement for 
endosomal acidification. Consistent with this, the TLR7-specific 
inhibitor, IRS-661, but not a control oligonucleotide, markedly 
blocked IFN-α production (Figure 1D). We confirmed that pDCs 
were the responsible cell type by demonstrating a marked reduc-
tion in IFN-α production when peripheral mononuclear cells were 
depleted of BDCA4+ cells prior to cocultivation with infected cells 
type I IFNs (14–17). Despite this, unlike the liver in acute hepatitis 
A, intrahepatic type I ISG expression is often robust in both acute 
and chronic hepatitis C (12, 18–20). In part, this may be due to the 
ability of pDCs to sense HCV-infected cells. pDCs are not stim-
ulated to produce IFN-α when incubated with high-titer purified 
HCV virions, but they are potently activated via TLR7 when cocul-
tured with virus-infected cells (21). This results from short-range 
exosomal transfer of HCV RNA from virus-infected cells to pDCs 
in a process dependent upon components of the cellular endosomal 
sorting complex required for transport (ESCRT) (22). Since the bio-
genesis of eHAV particles is also dependent upon ESCRT (11) and 
the intrahepatic abundance of HAV RNA exceeds that of HCV RNA 
by orders of magnitude during acute infection, despite much lower 
levels of intrahepatic ISG transcripts (12), we set out to character-
ize the interactions of enveloped and nonenveloped virions with 
freshly isolated human pDCs.
Results
HAV-infected cells, but not purified nonenveloped virions, stimulate 
human pDCs to produce IFN-α. We isolated BDCA4+ pDCs by 
positive selection from the blood of healthy human donors and 
characterized the pDC response to HAV in vitro. pDCs exposed 
to CpG-A (a TLR9 agonist) produced large quantities of IFN-α, 
but high concentrations of nonenveloped HAV virions failed to 
Figure 1. Coculturing with HAV-infected cells induces IFN-α production by pDCs. (A) pDCs (4 × 105/ml) were exposed to nonenveloped HAV (MOI = 20), 
either with or without anti-HAV antibody, or cocultured with HM175/p16 virus-infected cells (1 × 106/ml). Supernatant IFN-α was measured at 20 hours by 
ELISA. CpG DNA (ODN2216, 1 μM) was used as a positive control. LOD, limit of detection. (B) pDCs were exposed to influenza A virus (IAV, 6 HA units/ml),  
R848 (1 μM), or CpG in the presence or absence of HAV. (C) pDCs from multiple donors were exposed to CpG or HAV or cocultured with mock or HAV- 
infected Huh-7.5 cells or FRhK-4 cells for 20 hours. Red bars indicate median. (D) pDCs and HAV-infected cells were cocultured in the presence of mono-
clonal anti-HAV antibody or control IgG, following treatment with either bafilomycin A (BAF, 50 nM) or chloroquine (CLQ, 50 μM) or 1 μM TLR7 antagonist 
IRS-661 or control IRS. Results are representative of 2 independent experiments. (E) Total or pDC-depleted PBMCs (-pDC) were exposed to 1 μM CpG A or 
cocultured with mock or HAV-infected Huh-7.5 cells. (F) pDCs were cocultured with cells infected for increasing numbers of days. Supernatant IFN-α (bars) 
and intracellular HAV RNA (red line) are shown. GE, genome equivalents. (G) pDCs and HAV-infected cells were cocultured with or without separation by a 
permeable membrane (pore size = 1 μm). Data represent mean ± SEM in A, B, and D–G.
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specific for HAV RNA and used an enzyme 
assay to track acetylcholinesterase (AChE), 
which is present on exosome membranes 
(25, 26). AChE activity peaked in frac-
tions with a density of ~1.12 g/cm3 (fraction 
16), in contrast to eHAV, which banded at 
~1.08 g/cm3 (fraction 13) (Figure 2B). Our 
previous studies have demonstrated that 
programmed cell death 6 interacting pro-
tein (ALIX, also known as PDCD6IP), an 
ESCRT-associated protein involved in the 
biogenesis of both exosomes and eHAV, 
bands in 2 distinct peaks at these densi-
ties in similar gradients (11, 27). Remark-
ably, when incubated with pDCs, the 
fractions most efficiently triggering IFN-α 
production were those containing eHAV 
(Figure 2B). Moreover, the magnitude of 
IFN-α produced correlated strongly with 
the abundance of eHAV RNA (Figure 2C), 
which Northern blot analysis indicated was 
predominately genome length (Figure 2D). 
Taken collectively, these data suggest that 
eHAV, not exosomes containing fragments 
of HAV RNA, account for most pDC acti-
vation. To further resolve the pDC-stimu-
lating activity, isopycnic gradient fractions 
containing eHAV were subjected to a sec-
ond round of centrifugation in rate-zonal 
gradients (25). This allowed for separation 
on the basis of size and sedimentation 
velocity rather than density. The AChE 
activity that cobanded with eHAV in isopy-
cnic gradients sedimented more slowly 
than eHAV in rate-zonal gradients, peak-
ing in fractions 2–4 rather than fractions 
7–9 (Figure 2E). ALIX was present in both 
membrane fractions, while flotillin-1, which is associated with 
eHAV as well as exosomes (11), was detected only in the eHAV 
fractions (Figure 2E). pDC stimulation was largely confined to the 
eHAV-containing fractions. These results provide further evidence 
that pDCs are stimulated by eHAV, not more slowly sedimenting 
exosomes that do not contain encapsidated HAV genomes.
Efficient uptake of eHAV accounts for pDC activation. We con-
sidered the possibility that e preferential sensing of eHAV com-
pared with that of HAV by pDCs might reflect greater uptake of 
enveloped virions compared with that of nonenveloped virions. 
To test this, we incubated freshly isolated pDCs with equal quan-
tities of gradient-purified eHAV or HAV (quantified by RT-qPCR). 
The cells were washed extensively at intervals, and RNA was 
extracted to assess the quantity of cell-associated viral genomes. 
Substantially greater quantities of eHAV were associated with 
pDCs compared with nonenveloped HAV after 1 hour (Figure 
3A). Whereas the amount of cell-associated eHAV RNA remained 
stable or increased slightly over the ensuing 23 hours, the quan-
tity of cell-associated nonenveloped virion RNA progressively 
decreased. Consistent with this, only pDCs exposed to eHAV pro-
(Figure 1E). IFN-α production also correlated with the abundance 
of HAV RNA in infected cells (Figure 1F). Importantly, pDCs were 
stimulated only when in close proximity to HAV-infected cells and 
not when separated by a permeable membrane (Figure 1G). These 
findings parallel observations with HCV (21), and suggest that the 
weak intrahepatic ISG responses observed in acute hepatitis A (12) 
are not due to an inability of pDCs to sense HAV-infected cells.
Enveloped eHAV virions mediate pDC activation. Since highly 
concentrated preparations of nonenveloped virions do not stim-
ulate pDCs, it is likely that the IFN-α produced by pDCs, when 
cocultured with infected cells, reflects sensing of enveloped viri-
ons. Alternatively, HAV RNA may be transferred to pDCs as cargo 
within exosomes released by infected cells, as proposed for HCV 
(22). Consistent with either hypothesis, a 100-fold concentration 
of supernatant fluids from infected cells containing predomi-
nantly enveloped eHAV particles stimulated pDCs to produce 
IFN-α (Figure 2A). To resolve the activating material, we subjected 
concentrated cell culture fluids to ultracentrifugation in isopycnic 
iodixanol gradients to separate enveloped and nonenveloped viri-
ons (11). We identified virions in gradient fractions by RT-qPCR 
Figure 2. eHAV induces IFN-α production by pDCs. (A) Serial dilutions of concentrated supernatant 
(100,000-g pellet) from HAV-infected cells were mixed with pDCs (1 × 106/ml) and incubated for 20 hours. 
IFN-α levels (mean ± range in replicate assays) are plotted against HAV RNA content. Unconcentrated 
supernatant from infected (red arrow and triangle) and mock-infected (white square) cells were tested in 
parallel. (B) Concentrated supernatant fluids from HAV-infected cells were subjected to isopycnic gradient 
centrifugation, and individual gradient fractions were incubated with pDCs (1 × 106/ml). HAV RNA content 
of fractions was determined by RT-qPCR. IFN-α production shown represents results from 3 donors  
(mean ± SEM). AChE activity was measured by enzyme assay. (C) Correlation (Spearman’s test) between 
eHAV content of isopycnic gradient fractions, shown as genome equivalent per pDC, and IFN-α  
produced (mean ± range in replicate assays). (D) Northern blot of HAV RNA: full-length in vitro–transcribed 
HM175/18f HAV RNA, RNA extracted from peak isopycnic gradient fractions containing eHAV, or non-
enveloped HAV (mean ± range in replicate assays). (E) Consecutive gradient fractions containing eHAV 
from a gradient similar to that in B were pooled, concentrated, and subjected to rate-zonal ultracentri-
fugation. Fractions were collected from the top and assessed for HAV RNA content, AChE activity, and 
pDC stimulating activity (P105 and P106 indicate individual donors) (mean ± range in replicate assays). 
Representative results from 1 of 3 independent experiments are shown. Western blots of ALIX and  
flotillin-1 in the rate-zonal gradient fractions are shown.
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tion-incompetent version of the replicon, with a frame-shift muta-
tion in the polymerase coding sequence (HAV-Luc-Δ3D), stimu-
lated similar levels of IFN-α production (Figure 3E).
pDCs are transiently recruited to the liver during acute HAV infec-
tion. Since our data show that pDCs are capable of sensing HAV 
infection and secrete large amounts of IFN-α, we sought to under-
stand why a robust type I IFN response does not occur within the 
liver during acute hepatitis A. To determine whether pDCs are 
recruited to the liver, we studied available archived materials from 
2 chimpanzees that were previously experimentally infected with 
HAV (12). Immunofluorescence staining of sections of liver tissue, 
using both polyclonal and monoclonal antibodies against human 
C-type lectin domain family 4, member C (BDCA2, also known as 
CD303 or CLEC4C), a specific marker for pDCs, revealed numer-
ous BDCA2+ cells within sinusoidal spaces 1 week after virus chal-
lenge in both animals (Figure 4). In chimpanzee 4x0293, there 
was less than 1 BDCA2+ cell per 103 nucleated cells prior to intra-
venous challenge with HAV. This was unchanged 2 days after chal-
lenge but increased to 29 ± 9 BDCA2+ cells per 103 nucleated cells 
at 1 week, when intrahepatic expression of ISG15 and IFN- induced 
protein with tetratricopeptide repeats 1 (IFIT1) mRNA was max-
imal (12), then fell to 1.6 per 103 cells at 2 weeks (Figure 4A). 
pDC infiltration followed a similar kinetic pattern in chimpanzee 
4x0395, but ISG mRNA expression peaked somewhat later, at 2 
duced IFN-α (Figure 3A). Thus, eHAV is taken up more efficiently 
by pDCs compared with nonenveloped HAV, a property conferred 
by the envelope, and this is likely to account for the ability of eHAV 
to activate pDCs.
HAV does not encode any glycoproteins, and there is no evi-
dence suggesting that viral proteins exist on the surface of eHAV. 
Since the entry of many enveloped viruses is facilitated by TIM/
TAM family members binding phosphatidylserine (PtdSer) on 
their surface (28, 29) and since TIM1 is constitutively expressed 
by pDCs (30), we asked whether such an interaction plays a role in 
eHAV uptake. Indeed, recombinant annexin V (which binds Ptd-
Ser) (28) inhibited eHAV uptake by pDCs (Figure 3B). Annexin V 
also reduced IFN-α production by pDCs exposed to concentrated 
supernatant fluids from HAV-infected cell cultures (Figure 3C). 
However, antibody to TIM1 did not block eHAV uptake (data not 
shown), suggesting PtdSer receptors other than TIM1 are involved 
in eHAV uptake. Intriguingly, although TIM1 is considered to be 
the cellular receptor for nonenveloped HAV (24), nonenveloped 
virions were not taken up efficiently by pDCs.
HAV genome replication is not required for induction of IFN-α 
expression by pDCs, as neither UV inactivation nor an inhibitor 
of the HAV 3Cpro protease (31) diminished this response (Figure 
3D). We also found that pDCs could be activated by transfection 
of synthetic replicon RNA (HAV-Luc) into pDCs and that a replica-
Figure 3. Differential uptake of eHAV versus nonenveloped HAV by pDCs. (A) pDCs were exposed to equal quantities of gradient-purified eHAV or 
nonenveloped HAV, and cell-associated viral RNA and supernatant IFN-α levels were determined at intervals. Circles and squares represent cells from 2 
individual donors, respectively. (B) pDCs were incubated with eHAV in the presence or absence of annexin V (2 or 10 μg/ml), and cell-associated viral RNA 
was determined at intervals by RT-qPCR. (C) IFN-α produced by pDCs exposed to concentrated supernatant fluids from mock- or HM175/p16-infected 
cell cultures in the presence or absence of annexin V (2 μg/ml). (D) IFN-α produced by pDCs exposed to gradient-purified eHAV following inactivation by 
UV light or cultured with eHAV in the presence of 100 μM HAV 3Cpro inhibitor (3C-inh) (EC90 = 62 μM, CC50 = 3 mM). Efficiency of UV inactivation and 3C 
inhibitor treatment. Huh-7.5 cells were infected with UV-inactivated eHAV or nontreated eHAV in the presence of 3C-inh, and cell-associated HAV RNA was 
measured by RT-qPCR and compared with that in cells infected with untreated HAV at 48 hours. (E) pDCs were transfected with HM175/18f genomic RNA 
in the presence and absence of IRS-661 or subgenomic HAV-luc RNA or a replication incompetent variant HAV-Luc-Δ3D. Supernatant IFN-α levels were 
measured by ELISA. Results represent the mean ± SEM (n = 2 or 3 cultures) obtained with pDCs from single donors.
The Journal of Clinical Investigation   R e s e a R c h  a R t i c l e
1 7 3jci.org   Volume 125   Number 1   January 2015
The efficient sensing of HAV-infected cells by pDCs (Figure 
1C) parallels previous observations with HCV (21). An important 
distinction, however, is that activation of pDCs results from rec-
ognition of enveloped eHAV virions released by these cells (Figure 
2) and not viral RNA-laden exosomes as suggested for HCV (22). 
The preferential sensing of eHAV compared with that of nonen-
veloped virions by freshly isolated human pDCs reflects distinct 
interactions of these particles at the level of cell attachment and/
or endocytosis (Figure 3A). The membrane that wraps the capsid 
in the eHAV virion undoubtedly plays a key role in this process. 
PtdSer is often present on the membrane of enveloped viruses and 
promotes cellular attachment and entry of these viruses via inter-
actions with TIM/TAM family proteins (28, 29). The partial inhi-
bition of pDC uptake of eHAV by annexin V (Figure 3B) suggests a 
role for PtdSer, but it remains possible that unknown cellular pro-
teins associated with the membrane contribute to this process. An 
alternative possibility is that eHAV is internalized by macropino-
cytosis, a nonspecific fluid-based endocytic mechanism that is 
constitutively active in pDCs (32).
The inhibition of IFN-α secretion following treatment with 
IRS-661 suggested that eHAV activates pDCs mainly via TLR7 
(Figure 1D), although a minor contribution from the cytoso-
lic pathogen recognition receptors RIG-I and MDA5 cannot be 
excluded. TLR7 sensing presumably occurs after degradation of 
the eHAV membrane within a late endosomal/lysosomal compart-
ment (11). How TLR7 then gains access to the RNA that remains 
fully encapsidated after degradation of the eHAV membrane is 
weeks (Figure 4B). Importantly, eHAV was present in the blood of 
both animals at week 1 (11, 12). Viremia peaked at weeks 2–3 and 
then declined rapidly, despite persistence of viral RNA in the liver.
Cytokine ELISA demonstrated the presence of low levels of 
circulating IFN-α in both animals (Figure 4). This peaked at 14 
to 27 pg/ml 1 to 2 weeks after virus challenge, prior to maximal 
intrahepatic viral RNA abundance or serum ALT elevation (ref. 12 
and Figure 4). Sampling intervals in these previous chimpanzee 
studies were insufficient to determine whether pDC infiltration, 
serum IFN-α levels, and intrahepatic ISG expression were tempo-
rally related. However, the data show that pDCs are recruited to 
the liver early in HAV infection but disappear many days before 
viral replication peaks and inflammation develops.
Discussion
Since HAV infections are almost always controlled and eliminated 
by host immunity, an understanding of how the virus is sensed 
by the host provides important insight into a successful antiviral 
immune response. Data presented here advance our knowledge of 
the immune response in hepatitis A and indicate that the absence of 
strong type I ISG expression within the liver relates, at least in part, 
to the absence of a continuing presence of pDCs, not an inability of 
pDCs to sense the infection. Although the membrane enveloping 
eHAV sequesters the viral capsid and protects it from neutralizing 
antibodies while circulating in the host (11), it enhances the visibil-
ity of the virus to pDCs and may account for the minimal type I IFN 
response observed early in acute infection (12).
Figure 4. pDCs are transiently recruited to the livers of HAV-infected chimpanzees. (A) Serum IFN-α and changes in intrahepatic ISG15 and IFIT1 mRNA 
abundance are shown together with levels of intrahepatic HAV RNA in a chimpanzee, 4x0293, experimentally infected with HAV. The ISG15 response and 
virologic events have been described previously (12). Sections of archived liver specimens collected from chimpanzee 4x0293 at indicated times prior to and 
after intravenous challenge with HAV were stained with rabbit polyclonal antibody to human BDCA2. (B) Serum IFN-α and ISG15 and IFIT1 mRNA and ALT 
activities and intrahepatic HAV RNA in chimpanzee 4x0395 that was similarly infected with HAV (12). Sections of archived liver biopsies from 4x0395 were 
stained with murine monoclonal antibody 15B to human BDCA2. Scale bars: 200 μm. 
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unclear. Little is known about HAV uncoating and how encapsi-
dated RNA reaches the cytoplasm. The RNA genome of poliovi-
rus (a well-studied picornavirus) is transferred directly across the 
endosomal membrane into the cytoplasm via an umbilicus that 
forms as a result of interactions of the capsid with its receptor 
(33). The HAV genome may be similarly transferred, but recent 
crystallographic studies of the HAV capsid suggest a fundamental 
difference in the mechanism of uncoating and raise the possibility 
that encapsidated RNA is taken up into the cell intact, with disas-
sembly occurring subsequently within the cytoplasm (34). Either 
way, it is unlikely that HAV RNA is released into the endosomal 
lumen during entry of the virus. One possibility is that cytosolic 
HAV RNA traffics to the TLR7 compartment via an autophagy-de-
pendent process (35). Alternatively, a fraction of virions could be 
degraded in the lysosome, allowing viral RNA to be exposed to 
TLR7. Yet a third scenario is that nonencapsidated viral RNA may 
be adventitiously packaged into eHAV during the envelopment of 
the capsid and that these RNA molecules, embedded between the 
enveloping membrane and the capsid, are released upon mem-
brane degradation. It is interesting to note, however, that the viral 
RNA present within the activating eHAV particles was predomi-
nantly if not exclusively of genome length (Figure 2D), consistent 
with it being entirely encapsidated.
The lack of a strong type I ISG response within the liver 
during acute hepatitis A (12) can be attributed to the absence 
of pDCs within the liver during the peak phase of the infection 
coupled with the cleavage of both MAVS and TRIF by HAV pro-
teases (14, 15). The signals that result in the initial recruitment 
of pDCs to the liver early in the course of the infection (Figure 
4) are unknown. It is interesting, however, that the pDCs we 
identified within the liver during the first week of the infection 
were distributed within the hepatic sinusoids (Figure 4) and not 
clustered near portal tracts in which inflammatory cells are typ-
ically found. The fate of these pDCs and why their numbers are 
reduced within the liver at later time points are equally uncertain. 
One possibility is that they undergo conversion to conventional 
DCs, with reduced type I IFN production (2). Alternatively, they 
may undergo apoptosis (36, 37).
While the early intrahepatic type I IFN response in chimpan-
zee 4x0293 correlated well with the presence of pDCs in the liver, 
the presence of pDCs appears to have preceded intrahepatic ISG 
expression in chimpanzee 4x0395 (Figure 4). Thus, it is not clear 
whether the early and weak-type I IFN response results from pDC 
sensing of the virus or from RLRs or TLR3 prior to full expression 
of HAV proteases in infected cells. Either way, there is insufficient 
type I IFN to impair replication of the virus. In mice, T cell prim-
ing requires antigen receptor ligation, costimulation, and direct 
inflammatory stimulation with signal 3 cytokines. Type I IFN is 
an essential signal 3 cytokine for generation of functional acute-
phase CD4+ and CD8+ T cells (38, 39). The time-limited engage-
ment of pDCs and restricted type I IFN response that accompany 
HAV infection are sufficient to support the development of robust 
CD4+ T cell and B cell responses and to eliminate the virus over 
time (12, 40). However, whether the type I IFN response is suffi-
cient for CD8+ T cell immunity is less certain, because the acute-
phase HAV-specific response to class I epitopes in these animals 
was weak and delayed (40).
Prolonged type I IFN signaling can facilitate virus persistence in 
mice (41). The transient and weak nature of the intrahepatic type I 
IFN response during acute hepatitis A contrasts sharply with the pro-
longed, robust response during acute hepatitis C (12, 20). pDCs do 
accumulate in the liver during the chronic phase of HCV infection (42, 
43), but whether they infiltrate liver during the acute phase of infection 
has not been studied. A strong, prolonged pDC response during acute 
HCV infection compared with a temporally limited, restricted pDC 
response during HAV infection could provide a partial explanation for 
the difference in persistence of these viruses in humans.
Methods
Reagents and antibodies. Chemical reagents were purchased from Sig-
ma-Aldrich unless otherwise noted. CpG A ODN2216 and R848 were 
purchased from Invivogen. IRS-661 and a related control oligonucle-
otide (5′-TCCTGCAGGTTAAGT-3′) were synthesized by Integrated 
DNA Technologies. Influenza A virus (PR8 strain) was obtained from 
Charles River Laboratory. An HAV 3Cpro protease inhibitor (44) was 
provided by Bruce Malcolm (Tibotec, Mechelen, Belgium). Human 
convalescent sera (JC plasma) containing high-titer anti-HAV anti-
body was collected 90 days after the onset of hepatitis A (11). Rabbit 
polyclonal and mouse monoclonal antibodies to human BDCA2 were 
gifts from Liguo Zhang (Institute of Biophysics, Chinese Academy 
of Sciences, Beijing, China) (45). Monoclonal anti-TIM1 3D1 was a 
gift from Rosemarie DeKruyff (Boston Children’s Hospital, Boston, 
Massachusetts, USA), and monoclonal anti-HAV K2-4F2 was from 
Commonwealth Serum Laboratories.
Cells and viruses. Huh-7.5 (46) and FRhK-4 cells (47) were cultured 
in DMEM supplemented with 10% FBS, penicillin, and streptomycin. 
HAV strains HM175/18f and p16 were described previously (11). High-
titer HAV stock was prepared by infecting Huh-7.5 cells at low MOI and 
freeze thawing the infected cells 3 times to release the virus. Nonenvel-
oped virions were prepared by clarifying lysates by low-speed centrifu-
gation, followed by sonication and extraction with an equal volume of 
chloroform. Enveloped virions were concentrated from supernatants 
of HAV-infected culture collected between 2 and 6 weeks after inoc-
ulation by differential centrifugation, as described below. Infectious 
virus titers were determined by a modified infectious focus-forming 
assay (IR-FIFA) (11).
pDC isolation and stimulation. The BDCA-4 Microbead Kit (Mil-
tenyi Biotec) was used to isolate human pDCs from healthy donor 
buffy coats purchased from the New York Blood Center. All donations 
tested negative for hepatitis B virus, HCV, and human immunodefi-
ciency virus. Freshly isolated pDCs (between 2 × 104 and 1 × 105 cells 
per well, 85%–95% purity) were cultured in flat bottom 96-well plates 
in RPMI-1640 medium supplemented with 10% FBS and penicillin 
and streptomycin and were exposed to ligands (R848, CpG), gradient 
fractions, or cocultured with Huh-7.5 or FRhK-4 cells (1 × 105 cells per 
well) that were either uninfected or infected with HAV. For Transwell 
assays, pDCs and Huh-7.5 cells were separated by a membrane with a 
pore size of 1 μM (BD Biosciences). Supernatant fluids were collected 
at approximately 20 hours unless otherwise indicated. Supernatant 
IFN-α levels were determined with the human IFN-α ELISA Kit (PBL 
Interferon Source) following the manufacturer’s suggested procedure.
Isopycnic gradient centrifugation of virus. Huh-7.5 cells infected 
with HAV were cultured in DMEM medium supplemented with 10% 
exosome-free FBS (prepared by centrifugation at 100,000 g over-
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night). Cell culture supernatant fluids were concentrated by differen-
tial centrifugation (1,000 g for 10 minutes at 4°C, followed by centrif-
ugation at 10,000 g for 30 minutes twice) to remove debris and large 
vesicles. The clarified supernatant was subjected to ultracentrifuga-
tion at 100,000 g for 1 hour at 4°C. The pellet was resuspended in PBS, 
loaded onto an 8% to 40% iodixanol gradient (Opti-Prep, Sigma-Al-
drich), and centrifuged at 141,000 g for 48 hours. Fractions were col-
lected from the top of the gradient, and the density of each was deter-
mined using a Bausch & Lomb Abbé refractometer.
Rate-zonal centrifugation. Samples were loaded onto a preformed 
6%–18% iodixanol gradient and centrifuged at 250,000 g in a SW55Ti 
rotor for 2 hours at 4°C in a Beckman ultracentrifuge. Approximately 
10 fractions were collected from the top of the gradient.
Enzymatic assay for AChE activity. AChE activity was measured 
as previously described (25). Briefly, 50 μl prewarmed gradient frac-
tions were mixed with 50 μl reaction buffer containing 1.25 mM acet-
ylthiocholine and 0.1 mM 5,5-dithio-bis (2-nitrobenzoic acid), and the 
OD412 was determined at 30-second intervals over a period of 10 min-
utes with a Synergy 2 (BioTek) microplate reader.
HAV-specific RT-qPCR assay. Total RNA from cells and from 
culture supernatants or gradient fractions were extracted with the 
RNeasy Kit and the QIAamp viral RNA Isolation Kit (Qiagen), respec-
tively. HAV RNA was measured by real-time reverse transcription 
quantitative PCR (RT-qPCR) with a synthetic RNA as standards as 
previously described (12). Intracellular viral RNA was normalized to 
total RNA levels.
Indirect immunofluorescence staining for BDCA2. Archived for-
malin-fixed, paraffin-embedded liver specimens from HAV-infected 
chimpanzees 4x0293 and 4x0395 (12) were collected prior to Decem-
ber 15, 2011. Sections were sequentially treated with xylene, 100% 
ethanol, 95% ethanol, and 70% ethanol, followed by antigen retrieval 
by boiling for 15 minutes. Subsequently, sections were fixed with 4% 
paraformaldehyde and permeabilized with 0.5% Triton-X 100 and 
then stained using the Tyramide Signal Amplification Kit (Invitrogen) 
following manufacture’s recommendations. Polyclonal and mono-
clonal anti-BDCA2 antibodies (45) were used to stain for pDCs (see 
legend for Figure 4). Alexa Fluor 488–conjugated goat anti-rabbit 
or anti-mouse antibodies (Invitrogen) were used as secondary anti-
bodies. The images were acquired with a Nikon Eclipse Ti-s inverted 
microscope system with NIS-Elements BR 3.10 acquisition software. 
The number of BDCA2+ cells per 103 DAPI-positive nucleated cells 
was determined by a semiautomated approach using Metamorph 7.1 
software (Molecular Devices). The mean number of nucleated cells 
counted per microscopic field was 1,717 ± 444 SEM.
Luminex. Luminex analysis for plasma cytokines and chemok-
ines was performed by the Immunology Core Laboratory at the 
Southwest National Primate Research Center under the supervision 
of Core Director Luis Giavedoni. Blood samples were collected in 
tubes containing EDTA, and cytokines and chemokines were mea-
sured in a 39-plex assay using a Luminex100 with xMAP multiana-
lyte platform (Millipore).
Statistics. Correlations were assessed using the Spearman non-
parametric method. Calculations were made using Prism 6 for Mac 
OS X (GraphPad Software).
Study approval. The purchase of buffy coats obtained from 
anonymous blood donors through the New York Blood Center was 
reviewed by the Institutional Review Board of The University of 
North Carolina at Chapel Hill and determined not to constitute 
human subjects research.
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